MedChemExpress

## Desoxycorticosterone pivalate

| Cat. No.: | HY-107917 |  |  |
| :---: | :---: | :---: | :---: |
| CAS No.: | 808-48-0 |  |  |
| Molecular Formula: | $\mathrm{C}_{26} \mathrm{H}_{38} \mathrm{O}_{4}$ |  |  |
| Molecular Weight: | 414.58 |  |  |
| Target: | Mineralocorticoid Receptor |  |  |
| Pathway: | Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor |  |  |
| Storage: | Powder | $-20^{\circ} \mathrm{C}$ | 3 years |
|  |  | $4^{\circ} \mathrm{C}$ | 2 years |
|  | In solvent | $-80^{\circ} \mathrm{C}$ | 6 months |
|  |  | $-20^{\circ} \mathrm{C}$ | 1 month |



## SOLVENT \& SOLUBILITY

In Vitro
DMSO : $5 \mathrm{mg} / \mathrm{mL}\left(12.06 \mathrm{mM}\right.$; ultrasonic and warming and heat to $\left.80^{\circ} \mathrm{C}\right)$

|  | Solvent Mass | 1 mg | 5 mg | 10 mg |
| :---: | :---: | :---: | :---: | :---: |
| Preparing Stock Solutions | 1 mM | 2.4121 mL | 12.0604 mL | 24.1208 mL |
|  | 5 mM | 0.4824 mL | 2.4121 mL | 4.8242 mL |
|  | 10 mM | 0.2412 mL | 1.2060 mL | 2.4121 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

Description

In Vivo

Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism ${ }^{[1][2]}$

A starting dosage of $1.5 \mathrm{mg} / \mathrm{kg}$ Desoxycorticosterone pivalate (DOCP) is effective in controlling clinical signs and serum electrolyte concentrations in the majority of dogs with PH . An additional dose reduction often is needed to maintain an injection interval of 28-30 days. Young and growing animals seem to need higher dosages ${ }^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[^0]
## Caution: Product has not been fully validated for medical applications. For research use only.

[^1]
[^0]:    [1]. Sieber-Ruckstuhl NS, et al. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019 May;33(3):1266-1271

[^1]:    Tel: 609-228-6898
    Fax: 609-228-5909
    E-mail: tech@MedChemExpress.com
    Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

